Trials / Completed
CompletedNCT04567602
A Study of Pulmonary Arterial Hypertension Participants Treated With Macitentan or Selexipag
Non-Interventional Study on Pulmonary Arterial Hypertension Patients Treated With Macitentan or Selexipag: Experience From an Italian Cohort (INSPECTIO)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 372 (actual)
- Sponsor
- Janssen-Cilag S.p.A. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the change from baseline to 12 months after study enrollment in the number of the following non-invasive risk criteria: World Health Organization Functional Class (WHO/FC), 6-minute walk distance (6MWD), Brain Natriuretic Peptide (BNP) or N-terminal pro-brain Natriuretic Peptide (NT-proBNP).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PAH medication | There will be no specific interventions. |
Timeline
- Start date
- 2020-10-06
- Primary completion
- 2024-01-25
- Completion
- 2024-03-05
- First posted
- 2020-09-28
- Last updated
- 2025-06-25
Locations
30 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT04567602. Inclusion in this directory is not an endorsement.